Cargando…
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol
BACKGROUND: BRCA1 and BRCA2 genes are critical in homologous recombination DNA repair and have been implicated in familial breast and ovarian cancer tumorigenesis. Tumour cells with these mutations demonstrate increased sensitivity to cisplatin and poly (ADP-ribose) polymerase (PARP) inhibitors. 6MP...
Autores principales: | Nicum, Shibani, Roberts, Corran, Boyle, Lucy, Kopijasz, Sylwia, Gourley, Charlie, Hall, Marcia, Montes, Ana, Poole, Christopher, Collins, Linda, Schuh, Anna, Dutton, Susan J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301834/ https://www.ncbi.nlm.nih.gov/pubmed/25526776 http://dx.doi.org/10.1186/1471-2407-14-983 |
Ejemplares similares
-
Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours
por: Roberts, Corran, et al.
Publicado: (2019) -
EFFECT OF 6-MERCAPTOPURINE (6-MP) ON DIFFERENT CLASSES OF ANTIBODY
por: Borel, Yves, et al.
Publicado: (1965) -
On the Action of Methotrexate and 6-Mercaptopurine on M. avium Subspecies paratuberculosis
por: Greenstein, Robert J., et al.
Publicado: (2007) -
Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation
por: Choi, Yong Won, et al.
Publicado: (2015) -
Dietary polyphenols influence antimetabolite agents: methotrexate, 6-mercaptopurine and 5-fluorouracil in leukemia cell lines
por: Mahbub, Amani, et al.
Publicado: (2017)